Omega Therapeutics (NASDAQ:OMGA – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Omega Therapeutics to similar companies based on the strength of its analyst recommendations, risk, profitability, institutional ownership, dividends, valuation and earnings.
Insider and Institutional Ownership
88.9% of Omega Therapeutics shares are held by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.0% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Omega Therapeutics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Omega Therapeutics Competitors||1645||5714||11361||210||2.54|
Omega Therapeutics currently has a consensus target price of $29.50, indicating a potential upside of 854.69%. As a group, “Biological products, except diagnostic” companies have a potential upside of 120.52%. Given Omega Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Omega Therapeutics is more favorable than its competitors.
Earnings & Valuation
This table compares Omega Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Omega Therapeutics||$140,000.00||-$68.28 million||-0.65|
|Omega Therapeutics Competitors||$773.46 million||$147.16 million||-0.02|
Omega Therapeutics’ competitors have higher revenue and earnings than Omega Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Omega Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Omega Therapeutics Competitors||-4,043.00%||-66.82%||-29.84%|
Omega Therapeutics beats its competitors on 6 of the 11 factors compared.
About Omega Therapeutics (Get Rating)
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.